Placebo-controlled phase III study of lenograstim (Glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: Factors influencing chemotherapy administration

Leukemia and Lymphoma

Volumn 25, Issue 3-4, 1997, Pages 289-300

  Gisselbrecht, Christian ^a   Haioun, Corinne ^a   Lepage, Eric ^a   Bastion, Yves ^a   Tilly, Hervé ^a   Bosly, André ^a   Dupriez, Brigitte ^a   Marit, Gerald ^a   Herbrecht, Raoul ^a   Deconinck, Eric ^a   Marolleau, Jean Pierre ^a   Yver, Antoine ^a   Dabouz Harrouche, Farida ^a   Coiffier, Bertrand ^a   Reyes, Felix ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; MITOXANTRONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINDESINE;

ADOLESCENT; ADULT; ARTICLE; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HUMAN; INFECTION COMPLICATION; INJECTION PAIN; INJECTION SITE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUTROPENIA; NEUTROPHIL; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 8244221002     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709114168     Document Type: Article

References (29)

1. Devesa, S. S. and Fears, T. (1992). Non Hodgkin's lymphma time trends: United States and International Data. Cancer Res., (Supp) 52, 5432S-5440S.
2. Longo, D. L . De Vita, V. T., Duffey, P. L., Wesley, M. N., Ihde, D. C., Hubbard, S. M., Gilliom, M., Jaffe, E. S., Cossman, J., Fisher, R. I. and Young, R. C. (1991). Superiority of Pro-MACE-Cytabom over ProMace-MOPP in the treatment of advanced diffuse aggressive lymphoma: Results of a prospective randomized trial. J Clin. Oncol., 9, 25-38.
3. Shipp, M. A., Harrington, D. P., Klatt, M. M., Jochelson, M. S., Pinkus, G. S., Marshall, J L , Rosenthal, D. S., Skarin, A. T. and Canellos, G. P. (1986). Identification of major prognostic subgroups of patient with large-cell lymphoma treated with m-BACOD or M-BACOD, Ann. Intern. Med., 104, 757-765.
4. Klimo, P and Connors, J. M. (1987). Updated clinical experience with MACOB-B, Semin. Hematol., 24, 26-34 (suppl. 1).
5. Fisher, R. I., Gaynor, E., Dahlberg, S., Oken, M. M., Grogran, T. M., Mize, E. M., Glick, J. H., Coltman, C. A. Jr. and Miller, T. P. (1993). Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non- Hodgkin's lymphoma, N. Engl. J. Med., 328, 1002-1006.
6. Coiffier, B., Gisselbrecht, C., Herbrecht, R., Tilly, H., Bosly, A. and Brousse, N. (1989). LNH84 regimen: A multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma, J Clin. Oncol. 7, 1018-1026.
7. Coiffier, B., Tilly, H., Bosly, A., Sebban, C., Herbrecht, R. and Gisselbrecht, C. for the GELA. (1993). Long-term followup of the 737 aggressive lymphoma patients treated in the LNH84 protocol: Very few relapses after 5 years, Blood. 82, 1760 (abstract).
8. Haioun, C., Lepage, E., Gisseibrecht, C., Coiffier, B., Bosly, A., Tilly, H., Morel, P., Nouvel, C., Herbrecht, R., D'Agay, M. F., Gaulard, P. and Reyes, F. for the Groupe d'Etude des Lymphomes de l'Adulte. (1994). Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non Hodgkin's lymphoma in first complete remission: A study of 464 patients, J. Clin. Oncol., 12, 2543-2551.
9. Lepage, E., Gisselbrecht, C., Haioun, C., Sebban, C., Tilly, H., Bosly, A., Morel, P., Herbrecht, R., Reyes, F. and Coiffier, B. reporting for the GELA (1993). Prognostic significance of received relative dose intensity in non Hodgkin's lymphoma patients: Application to LNH87 protocol, Ann. Oncol., 4, 651-656.
10. Pettengell, R., Gurney, H., Radford, J. A., Deakin, D. P., James, R., Wilkinson, P. M., Kane, K., Bentley, J. and Crowther, D. (1992). Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood, 80, 1430-1436.
11. Gerhartz, H. H., Engelhard, M., Meusers, P., Brittinger, G., Wilmanns, W., Schlimok, G., Mueller, P., Huhn, D., Musch, R., Siegert, W., Gerhartz, D., Hartlapp, J H., Thiel, E., Huber, C., Peschl, C., Spann, W., Emmeroch, B., Schadek, C., Westerhausen, M., Pees, H, W., Radtke, H., Engere, A., Terhardt, E., Schick, H., Binder, T., Fuchs, R., Hasford, J., Brandmaier, R., Stern, A. C., Jones, T. C., Ehrlich, H. J., Stein, H., Parwaresch, M., Tiemann, M. and Lenner, K. (1993) Randomized, double-blind, placebo-controlled, phase III study of recombinant human granocyte-macrophage colony- stimulating factor as adjunct to induction treatment of high- grade malignant non Hodgkin's lymphoma, Blood, 82, 8:2329-2339.
12. Linch, D. C., Scarffe, H., Proctor, S., Chopra, R., Taylor, P. R. A., Morgenstern, G., Cunningham, D., Burnett, A. K., Cawley, J. C., Franklin, I. M., Bell, A. J., Lister, T. A., Marcus, R. E., Newland, A. C., Parker, A. C. and Yver, A. (1993). Randomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation, Bone Marrow Transplantation, 11, 307-311.
13. Marty, M (1994). The optimal dose of glycosylated recombinant human granulocyte colony stimulating factor for use in clinical practice: A review. Eur. J. Cancer, 30A, S20-S25.
14. Gisselbrecht, C., Prentice, H. G., Bacigalupo, A., Biron, P., Milpied, N., Rubie, H., Cunningham, D., Legros, M., Pico, J. L., Lmch, D. C., Burnett, A. K., Scarffe, J. H., Siegert, W. and Yver, A. (1994). Placebo-controlled phase III trial lenograstim in bone marrow transplantation, Lancet, 343, 696-700
15. Chevallier, B., Chollet, Ph., Merrouche, Y., Roche, H., Fumoleau, P., Kerbrat, P., Genot, J. Y., Fargeot, P., Oliver, J. P., Fizarnes, C., Clavel, M., Yver, A. and Cour Chabernaud, V. (1995). Lenograstim (rHuG-CSF) prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer, J. Clin. Oncol., 13, 1564-1571.
16. The Non-Hodgkin's Lymphoma Pathologic Classification Project: (1982). National Cancer Institute sponsored study of classiciations of non Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage, Cancer, 49, 2112-2135.
17. Carbone, P. P., Kaplan, H. S. and Musshoff, K. (1971). Report of the committee on Hodgkin's disease staging, Cancer Res., 31, 1860-1861.
18. The International non Hodgkin's lymphoma prognostic factors project: (1993). A predictive model for aggressive non Hodgkin's lymphoma, N. Engl. J. Med., 329, 987-994.
19. Kaplan, E. L. and Meier, P. (1958). Nonparametric estimation from incomplete observation, J. Am. Stat. Assoc., 53, 547-581.
20. Mantel, N. (1966). Evaluation of survival data and two new rank order statistics arising in its consideration, Cancer Chemother. Rep., 50, 163-170.
21. Hryniuk, W. M. (1988). The importance of dose intensity in the outcome of chemotherapy, In: De Vita, V. T. Hellmann, S. and Rosenberg, S A. (eds). Important advances in oncology. p. 121 Philadelphia P.A Lippincott.
22. Nissen, C., Dalle, C. V. and Moser, Y. (1994). In vitro comparison of the biological potency of glycosylated versus nonglycosylated rG-CSF, Drug Invest., 7, 346-352.
23. Ota, K., Ariyoshi, Y., Fukuoka, M., et al. (1990). Clinical effect of recombinant human G-CSF on neutropenia induced by chemotherapy for lung cancer, Jpn. J. Cancer Chemother., 17, 65-71.
24. Lyman, G. H., Lyman, C. G., Sanderson, R. A. and Balducci, L. (1993). Decision analysis of hematopoïetic growth factor use in patients receiving cancer chemotherapy, J. Natl. Cancer Inst., 85, 1935-1936.
25. Broxmeyer, H. E., Benninger, L., Patel, S. R., Benjamin, R. S. and Saroj Vadhan, R. A. J. (1994). Kinetic responses of human marrow myeloid progenitor cells to in vivo treatment of patients with granulocyte colony-stimulating factor is different from the response to treatment with granulocyte-macrophage colony-stimulating factor, Exp. Hematol., 22. 100-102.
26. Souetre, S and Qing, W (1994). Economic analysis of lenograstim in the correction of neutropenia following chemotherapy for non Hodgkin's lymphoma, Pharmaco-Economics, 6, 36-43.
27. Kauffman, C. A., Liepman, M. K., Bergman, A. G. and Mioduszewski, J. (1983). Trimethoprim/Sulfamethoxazole prophylaxis in neutropenic patients. Amer. J. Med., 74, 599.
28. Talcott, J. A., Siegel, R. D., Finberg, R. and Goldman, L. (1992) Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule, J. Clin. Oncol., 10, 316-322.
29. Rubenstein, E. B., Rolston, K., Benjamin, R. S., Loewy, J., Escalante, C., Manzullo, E., Hughes, P., Moreland, B., Fender, A., Kennedy, K., Holmes, F., Elting, L. and Bodey, G. P. (1993). Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer, 71, 3640-3646.